3-hydrazino-4H-pyrido[4,3-e]-1,2,4-thiadiazine 1,1-dioxide | 193681-70-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3-hydrazino-4H-pyrido[4,3-e]-1,2,4-thiadiazine 1,1-dioxide
• 英文别名: (1,1-dioxo-4H-pyrido[4,3-e][1,2,4]thiadiazin-3-yl)hydrazine
• CAS: 193681-70-8
• 化学式: C₆H₇N₅O₂S
• 分子量: 213.22
• InChiKey: CGCLEZVDCLMFNV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.6
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  118
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  3-methylsulfanyl-4H-pyrido<4.3-e>-1,2,4-thiadiazine 1,1-dioxide 在 肼 作用下， 以 水 为溶剂， 反应 0.5h， 生成 3-hydrazino-4H-pyrido[4,3-e]-1,2,4-thiadiazine 1,1-dioxide
  参考文献：
  名称：

  PYRIDO-1,2,4-THIADIAZINE AND PYRIDO-1,4-THIAZINE DERIVATIVES, THEIR PREPARATION AND USE

  摘要：

  公开号：

  EP0877748B1

文献信息

• Pyrido-1,2,4-thiadiazine and pyrido-1,4-thiazine derivatives, their
  申请人：Novo Nordisk A/S

  公开号：US05792764A1

  公开（公告）日：1998-08-11

  Pyrido-1,2,4-thiadiazine and pyrido-1,4-thiazine derivatives represented by the formula ##STR1## wherein A, B, D, R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are defined in the description, compositions thereof and methods for preparing the compounds are described. The compounds are useful in the treatment of diseases of the central nervous system, the cardiovascular system, pulmonary system, the gastrointestinal system and the endocrinologic system.

  Pyrido-1,2,4-噻二嗪和由以下式表示的Pyrido-1,4-噻嗪衍生物##STR1##其中A、B、D、R.sup.1、R.sup.2、R.sup.3和R.sup.4在描述中有定义，描述了它们的组成物和制备化合物的方法。这些化合物在治疗中枢神经系统、心血管系统、肺部系统、胃肠系统和内分泌系统疾病中有用。
• Use of potassium channel agonists for the treatment of cancer
  申请人：——

  公开号：US20020028808A1

  公开（公告）日：2002-03-07

  The present invention relates to the use of potassium channel agonists for treating cancer, more particular the treatment and/or prevention of breast cancer and endometrial cancer. The present invention also embraces the use of the compounds of general formulas (I) and (Ia) in treating cancer and methods of using the compounds and their pharmaceutical compositions.

  本发明涉及使用钾通道激动剂治疗癌症，更具体地说是治疗和/或预防乳腺癌和子宫内膜癌。本发明还包括使用一般式(I)和(Ia)的化合物治疗癌症以及使用这些化合物及其药物组合物的方法。
• Use of potassium channel agonists for reducing fat food consumption
  申请人：——

  公开号：US20020035106A1

  公开（公告）日：2002-03-21

  The present invention relates to the use of potassium channel agonists for reducing or lowering the consumption of fat food. The present invention also embraces the use of the compounds of general formulas (I) and (Ia) in reducing or lowering the intake of fat food and methods of using the compounds and their pharmaceutical compositions.

  本发明涉及使用钾通道激动剂减少或降低脂肪食物的摄入量。本发明还包括通式（I）和（Ia）化合物在减少或降低脂肪食物摄入量方面的用途，以及使用这些化合物及其药物组合物的方法。
• Use of selective potassium channel openers
  申请人：——

  公开号：US20030125323A1

  公开（公告）日：2003-07-03

  The present invention relates to a use of SUR1/Kir6.2 selective potassium channel openers for the preparation of a pharmaceutical composition for the prevention or the treatment of diabetes, and for the treatment of hyperinsulinaemia and hyperandrogenism in women with Polycystic Ovary Syndrome (PCOS) as well as a pharmaceutical composition for use in the prevention or the treatment of diabetes, and in the treatment of hyperinsulinaemia and hyperandrogenism in women with Polycystic Ovary Syndrome.

  本发明涉及利用 SUR1/Kir6.2 选择性钾通道开放剂制备一种药物组合物，用于预防或治疗糖尿病，以及治疗多囊卵巢综合征（PCOS）女性患者的高胰岛素血症和高雄激素症，还涉及一种药物组合物，用于预防或治疗糖尿病，以及治疗多囊卵巢综合征女性患者的高胰岛素血症和高雄激素症。
• Combined use of a modulator of CD3 and a beta cell resting compound
  申请人：——

  公开号：US20030235583A1

  公开（公告）日：2003-12-25

  Methods and uses for the prevention and intervention of Type 1 diabetes and LADA comprising administration of a modulator of CD3 and a beta cell resting compound.

  预防和干预 1 型糖尿病和 LADA 的方法和用途，包括服用 CD3 调节剂和β细胞静止化合物。